Open AccessAssociation between renin–angiotensin–aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment
Author(s) -
Alexandre Lahens,
Jimmy Mullaert,
Simon B. Gressens,
Nathalie Gault,
Martin Flamant,
Laurène Deconinck,
Véronique Joly,
Yazdan Yazdanpanah,
François Xavier Lescure,
Emmanuelle VidalPetiot
Publication year - 2020
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/hjh.0000000000002658
Subject(s) - medicine , interquartile range , odds ratio , confidence interval , medical prescription , retrospective cohort study , logistic regression , pharmacology
The role of renin-angiotensin-aldosterone system (RAAS) blockers during the coronavirus disease 2019 (COVID-19) pandemic is a matter of controversies. Studies based on in-hospital exposure have suggested a beneficial effect of these drugs, unlike those based on chronic exposure. We aimed to analyse RAAS blocker prescription before and during hospital stay in patients with COVID-19, and the corresponding outcomes, to explain these discrepant results.